24919-37-7

Usage

Uses

Used in Pharmaceutical Industry:
3-Methyl-3,4-dihydro-1H-benzo[e][1,4]diazepine-2,5-dione serves as an active pharmaceutical ingredient for the development of medications targeting central nervous system disorders. Its use is primarily due to its ability to act as a sedative, hypnotic, or anxiolytic, providing relief for conditions such as anxiety and insomnia by depressing the central nervous system.
Used in Research and Development:
In the scientific community, 3-Methyl-3,4-dihydro-1H-benzo[e][1,4]diazepine-2,5-dione is utilized as a research compound for studying the effects of benzodiazepine derivatives on the nervous system. This helps in understanding the mechanisms of action and potential therapeutic benefits in treating neurological conditions.
Used in Drug Formulation:
3-Methyl-3,4-dihydro-1H-benzo[e][1,4]diazepine-2,5-dione is incorporated into drug formulations to enhance their efficacy in treating specific disorders. Its inclusion in formulations is based on its pharmacological properties, which can contribute to the overall therapeutic effect of the medication.

InChI:InChI=1/C10H10N2O2/c1-6-9(13)12-8-5-3-2-4-7(8)10(14)11-6/h2-6H,1H3,(H,11,14)(H,12,13)

Upstream product

• 68790-38-5 2-(tert-butyloxycarbonylamino)benzoic acid 
• 90-16-4 1,2,3-benzotriazin-4(3H)-one 
• 56-41-7 L-alanin 
• 118-48-9 isatoic anhydride 
• 302-72-7 rac-Ala-OH 

Relevant academic research and scientific papers

Simple synthesis, structure and ab initio study of 1,4-benzodiazepine-2,5- diones

A simple procedure for the synthesis of pyrido[2,1-c][1,4] benzodiazepine-6,12-dione (1) and 1,4-benzodiazepine-2,5-diones (2a-2d), using microwave irradiation and/or conventional heating is reported. The configuration of 1 was determined by single-crysta

A novel one step approach to the synthesis of 3H-1,4-benzodiazepin-(1H,4H)-2,5-diones from 1,2,3-benzotriazin-4-(3H)-one

1,2,3-Benzotriazin-4-(3H)-one(3) and its 6-chloro derivative (4) on thermal condensation with α-amino acids yielded 3H-1,4-benzodiazepin-(1H,4H)-2,5-diones(7-12) in moderate to good yield. The cyclocondensation is believed to proceed through the formation of an iminoketene intermediate (5).

Solid phase synthesis of 1,4-benzodiazepine-2,5-diones

1,4-benzodiazepine-2,5-diones were synthesized by a simple procedure utilizing polymer supported amino acids and o-nitrobenzoic acids or protected anthranilic acids. Cyclization of the common aminoamide intermediate with concomitant release from the support furnished the desired 1,4-benzodiazepine-2,5-diones. The products were recovered in high yields and exhibited excellent purities.

New routes to 1,4-benzodiazepin-2,5-diones

1,4-benzodiazepin-2,5-diones have been synthesized in good overall yields by two routes, the first one by cyclisation of dipeptides prepared from Boc anthranilic acid and α-amino acid methyl esters, the second one by reaction of N-carboxy α-amino acid anhydrides with Boc anthranilic acid.

New synthesis of 1,4 benzodiazepine-2,5-diones by means of HCl gas catalyst

A new synthesis of 1,4-benzodiazepinediones 4, particularly 1,4-dihydro1H-1,4-benzodiazepine-2,5-dione, 4c key intermediate of metabolites cyclopenin 9, cyclopenol 10, cyclopeptine 11 and dehydrocyclopeptide 12, was achieved by action of dry HCl gas in DM

A Versatile Synthesis of 3H-1(H),4(H)-Benzodiazepin-2,5-diones

Reaction of isatoic anhydrides (1) and α-amino acids (2) in glacial acetic acid under reflux gave 3H-1(H),4(H)-benzodiazepin-2,5-diones (3) in good yields.These compounds have been characterised by UV, IR, mass, PMR and 13C-NMR spectra.